# An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

> **NCT06668181** · PHASE3 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 40 (estimated)

## Conditions studied

- Enthesitis-related Arthritis
- Juvenile Psoriatic Arthritis

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT06668181
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2028-04-12
- **Final completion:** 2030-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668181, "An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06668181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*